Definium Therapeutics (DFTX) Net Equity Issued and Repurchased (2021 - 2023)

Definium Therapeutics (DFTX) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $2.6 million in Q4 2023.

• On a quarterly basis, Net Equity Issued and Repurchased rose 254.25% year-over-year to $2.6 million in Q4 2023; TTM through Sep 2025 was $2.6 million, a 62.98% decrease from a year earlier, with the FY2024 full-year figure at $984000.0, down 86.93% from the prior year.
• Net Equity Issued and Repurchased for Q4 2023 stood at $2.6 million, down from $3.1 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for DFTX reached as high as $82.1 million in Q1 2021 and fell as low as -$185000.0 in Q2 2021.
• Historically, Net Equity Issued and Repurchased has averaged $13.1 million across 3 years, with a median of $1.3 million in 2023.
• Across the five-year window, Net Equity Issued and Repurchased jumped 687600.0% in 2022 and slumped 88.73% in 2023, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at -$4000.0 in 2021, then soared by 18350.0% to $730000.0 in 2022, then jumped by 254.25% to $2.6 million in 2023.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $2.6 million in Q4 2023, $3.1 million in Q3 2023, and $1.3 million in Q2 2023.